

Bridge Bio confirms safety of BBT-401

12 November 2018 | News

Bridge Bio plans to initiate Phase II study in US within this year with patients with active UC diseases to see safety and efficacy at patients.



Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, has announced that BBT-401, the first anti-Pellino-1 compound currently under development for ulcerative colitis (UC) treatment, proved its safety and tolerability from phase I study.

BBT-401, a GI-tract restricted small molecule inhibitor of Pellino-1, was proved to be well tolerated and safe from Phase 1 Study, which is a randomized, double-blind study with 80 healthy volunteers. The most common adverse events were mild and recoverable diarrhea and mild headache. In addition, the PK data 1 demonstrated its key feature of no or minimal systemic exposure.

Bridge Bio plans to initiate Phase II study in US within this year with patients with active UC diseases to see safety and efficacy at patients.

BBT-401 was discovered by SKKU (Sungkyunkwan University) and KRICT (Korea Research Institute of Chemical Technology) and was licensed the exclusive worldwide right to Bridge Biotherapeutics in 2015.